Tyra Biosciences Statistics
Share Statistics
Tyra Biosciences has 52.87M shares outstanding. The number of shares has increased by 0.67% in one year.
| Shares Outstanding | 52.87M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.26% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 30.71M |
| Failed to Deliver (FTD) Shares | 70 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 2.53M, so 4.79% of the outstanding shares have been sold short.
| Short Interest | 2.53M |
| Short % of Shares Out | 4.79% |
| Short % of Float | 8.25% |
| Short Ratio (days to cover) | 10.54 |
Valuation Ratios
The PE ratio is -8.56 and the forward PE ratio is -8.2.
| PE Ratio | -8.56 |
| Forward PE | -8.2 |
| PS Ratio | 0 |
| Forward PS | 391.3 |
| PB Ratio | 2.9 |
| P/FCF Ratio | -11.62 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tyra Biosciences Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.8, with a Debt / Equity ratio of 0.
| Current Ratio | 13.8 |
| Quick Ratio | 13.8 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -37.93%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | -37.93% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.41M |
| Employee Count | 49 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 34.63% in the last 52 weeks. The beta is 1.08, so Tyra Biosciences 's price volatility has been higher than the market average.
| Beta | 1.08 |
| 52-Week Price Change | 34.63% |
| 50-Day Moving Average | 16.28 |
| 200-Day Moving Average | 18.68 |
| Relative Strength Index (RSI) | 53.56 |
| Average Volume (20 Days) | 340.76K |
Income Statement
| Revenue | n/a |
| Gross Profit | -353.00K |
| Operating Income | -79.94M |
| Net Income | -69.13M |
| EBITDA | -79.59M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.62 |
Balance Sheet
The company has 58.01M in cash and 6.50M in debt, giving a net cash position of 51.51M.
| Cash & Cash Equivalents | 58.01M |
| Total Debt | 6.50M |
| Net Cash | 51.51M |
| Retained Earnings | -164.83M |
| Total Assets | 380.59M |
| Working Capital | 353.24M |
Cash Flow
In the last 12 months, operating cash flow was -50.14M and capital expenditures -770.00K, giving a free cash flow of -50.91M.
| Operating Cash Flow | -50.14M |
| Capital Expenditures | -770.00K |
| Free Cash Flow | -50.91M |
| FCF Per Share | -1.19 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TYRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.36% |
| FCF Yield | -6.16% |
Analyst Forecast
The average price target for TYRA is $31, which is 98.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $31 |
| Price Target Difference | 98.3% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 23.84 |
| Piotroski F-Score | 3 |